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included drug cost and the reduced compliance of medication by
methylphenidate users (61%) versus AMP/DEX users (86%) and
the AMP/DEX response rate. CONCLUSIONS: Generic Adder-
allTM is the dominant strategy over generic RitalinTM given that
compliance and side effect rates are consistently higher for
generic AdderallTM. However, it is difﬁcult to make strong gen-
eralizations about cost-effectiveness between therapies given the
overlapping efﬁcacy rates and similar side effect proﬁles of com-
peting treatments as reported in the literature. Clinicians should
ﬁnd it appropriate to initiate stimulants in the short term regard-
less of the speciﬁc agent available.
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SUICIDE ATTEMPTS BY THE ELDERLY: HOSPITAL RESOURCE
USE AND COSTS
O’Brien J, Pitoniak-Morse C, Caro JJ
Caro Research Institute, Concord, MA, USA
OBJECTIVES: Reportedly, suicide rates are highest among those
aged 65 years and older (elderly) in the US. This study examines
admissions resulting from suicide attempts by elderly persons
and estimates the resulting hospital costs. METHODS: Cases of
suicide attempts by elderly persons were identiﬁed using ICD-9
diagnosis and E-codes. Hospital costs were developed based on
2000 discharge data from 619 hospitals in seven states, 
supplemented with national fee schedules. Cost estimates include
accommodation, ancillary and physician services, reported in
2003 US$. Charges were adjusted using a 0.61 cost-to-charge
ratio and the annual medical care component of the U.S. Con-
sumer Price Index. RESULTS: Of 2129 suicide attempts identi-
ﬁed, 56% were female and 3% were admitted from residential,
nursing or correctional facilities. The mean age was 76 years;
75% were admitted via Emergency Room and 41% spent time
in ICU. Drug overdose was the method of self-inﬂicted injury in
71% of cases. Mean length of stay was 5.9 days (median: 3,
range: 1–261). Mean cost per stay was $11,445 (median: $6005,
range: $498–$610,565). Cumulative cost for all cases was $29.7
million. The inpatient case fatality rate was signiﬁcantly (p =
0.000) higher in males (12%) than females (4%). Of those dis-
charged, 51% went home (6% with home care), 26% to sub-
acute facilities, 20% to a mental health or residential care facility,
and 1% returned to prison. Within 12 months following their
index suicide attempt, 8% were readmitted for another attempt
and survived. CONCLUSIONS: While most of the intentionally
self-inﬂicted injuries by elderly persons who are admitted to hos-
pital are not fatal, elderly males admitted for suicide attempts
are three times more likely to succeed. Although suicide attempts
by elderly persons generate substantial hospital costs, the 
estimates presented reﬂect only a portion of the economic 
consequences of this problem, as most require health services
post-discharge.
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OBJECTIVES: Evaluation of schizophrenic patients requires
measurements that extend, beyond mere estimation of psy-
chopathology symptoms, to assessment of quality of life levels.
The relationship between psychopathology and HRQOL
changes has not been extensively studied. The objective of this
study is to assess correlations between psychopathology (Posi-
tive and Negative Symptom Scale, PANSS) and a disease-speciﬁc
questionnaire, the Quality of Life Scale (QLS), in the evaluation
of schizophrenia patients. METHODS: An open-label, 52-week
follow–up study of 170 patients is being conducted in 8 Greek
public psychiatric hospitals. Patients with mild to moderate
schizophrenia (according to DSM-IV criteria) aged 18–65, hos-
pitalized or outpatients, newly diagnosed or in acute exacerba-
tion were enrolled. Psychopathology was assessed by PANSS
general psychopathology, positive and negative symptom scores.
HRQOL was assessed by QLS total and 4 subscale scores (inter-
personal relationships, instrumental role, intrapsychic founda-
tions and common objects and activities). Correlations analysis
was used to identify the relationship between PANSS and QLS
scores at baseline and at stabilization after 6-months treatment.
Six month follow-up data are presented in this analysis.
RESULTS: At baseline, a weak but statistically signiﬁcant (p <
0.001) association was found between the 4 QLS subscale scores
and PANSS general and negative symptom scores. Correlation
coefﬁcients ranged from r = -0.18 (p < 0.05) (QLS instrumental
role vs. PANSS negative) to r = -0.46 (p < 0.001) (QLS intrapsy-
chic foundation vs. PANSS negative). At six months a stronger
and statistically signiﬁcant association was observed. Correlation
coefﬁcients ranged from r = -0.32 (p < 0.001) (QLS total score
vs. PANSS general) to r = -0.56 (p < 0.001) (QLS intrapsychic
foundation vs. PANSS negative). CONCLUSIONS: The study
reveals a statistically signiﬁcant correlation between PANSS and
QLS at baseline scores, which is improved over the 6-months
follow-up period. HRQL measures and psychopathology seem
to change synchronically; the correlation is enhanced as the
control of schizophrenia symptoms is improved.
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DIFFERENTIAL IMPACT OF OLANZAPINE AND RISPERIDONE
ON SEXUAL DYSFUNCTION AND ITS POTENTIAL
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Ascher-Svanum H, Zhu B, Faries D, Jiang Q, Kinon BJ
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: Antipsychotics differ in their impact on prolactin,
and sustained elevation in prolactin levels is associated with
sexual dysfunction. Unlike risperidone, olanzapine is known 
as a prolactin-sparing antipsychotic. This study aimed to: a)
compare olanzapine and risperidone on reported sexual dys-
function during the long-term treatment of schizophrenia
patients in usual care, and b) examine the associations between
sexual dysfunction, medication adherence, and indicators of
well-being for all patients. METHOD: Data of the U.S. Schizo-
phrenia Care and Assessment Program (SCAP), a 3-year obser-
vational study of schizophrenia patients, were used to identify
participants who were treated with olanzapine (N = 330) or
risperidone (N = 216) at enrollment and continued on the drug
for a minimum of 1 year. The SCAP-Health Questionnaire was
used to measure patients’ self-reported medication-related sexual
dysfunction at 6-month intervals. Group differences on changes
in sexual dysfunction levels from baseline up to 3 years were
examined using a mixed model with repeated measures
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(MMRM). Pearson correlations examined the associations
between sexual dysfunction, medication adherence and indica-
tors of well-being. RESULTS: Compared to risperidone-treated
patients, those treated with olanzapine reported signiﬁcantly
greater long-term improvements in medication-related sexual
dysfunction (p < 0.001). Greater sexual dysfunction was signif-
icantly (p < 0.05) associated with greater emotional distress,
poorer mental functioning, lower life satisfaction, less satisfac-
tion with social life, and poorer self-reported medication 
adherence. CONCLUSION: Treatment with risperidone was
associated with greater sexual dysfunction compared to olanza-
pine. Findings suggest that minimizing treatment-related sexual
dysfunction may decrease emotional distress, improve life satis-
faction, and increase adherence with medication.
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OBJECTIVES: This study examined whether remission of psy-
chotic symptoms is associated with favorable long-term func-
tional and health-related quality of life (HRQOL) outcomes 
in the treatment of schizophrenia patients in usual care.
METHODS: We used data from the United States Schizophre-
nia Care and Assessment Program (SCAP), a 3-year observa-
tional study of schizophrenia, in which participants were
assessed at enrollment and 12-month intervals. Remission of psy-
chotic symptoms was deﬁned using the Remission in Schizo-
phrenia Working Group expert consensus criteria. Functional
and HRQOL outcomes were assessed with validated measures.
Four patient groups were compared on long-term outcomes: con-
tinuously remitted patients (R Æ R, N = 229); continuously non-
remitted patients (NR Æ NR, N = 1110); patients who changed
from non-remitted to remitted and stayed remitted (NR Æ R, 
N = 234); and patients who changed from remitted to non-
remitted and stayed non-remitted (R Æ NR, N = 202). Analysis
employed Generalized Estimating Equation (GEE) and mixed
models with repeated-measures. RESULTS: The R Æ R group
had signiﬁcantly better outcomes than the NR Æ NR and R Æ
NR groups on measures of productivity and occupational func-
tioning, social activity, daily activity, Global Assessment of Func-
tioning (GAF), mental health, quality of life, and life satisfaction.
The NR Æ R group did not signiﬁcantly differ from the R Æ R
group on most measures, but had signiﬁcantly poorer quality of
life, daily activity, GAF, and occupational functioning. CON-
CLUSIONS: In this large prospective naturalistic study, remis-
sion of psychotic symptoms was associated with a broad range
of favorable long-term functional and HRQOL outcomes. Find-
ings highlight the importance of achieving and maintaining
symptomatic remission in the long-term treatment of schizo-
phrenia patients in usual practice settings.
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OBJECTIVES: To explore the feasibility of estimating a prefer-
ence based utility score for the SQLS-R4 by mapping it onto the
utility scores generated from the published SF-6D and EQ-5D
tariffs. METHODS: The study consisted of a sample of 156
people with schizophrenia who completed the SQLS-R4, EQ-5D
and the SF-36. To facilitate regression modelling both sets of
scores were subtracted from unity to give utility decrement on
the scale zero to positive inﬁnite. In the regression models the
utility decrements were entered as dependent variables with the
three levels of SQLS-R4 data [total score, domain scores, indi-
vidual items scores] acting as explanatory variables. For each of
the levels two models were considered each for the EQ-5D and
SF-6D, the standard OLS model and a gamma distribution GLM
with the canonical log link. RESULTS: For both the EQ-5D and
SF-6D models as the number of explanatory variables increased
so did the variance explained by the data (R2), with a gradual
steady increase for the SF-6D, compared to a much sharper
increase from 43% to 55% for the EQ-5D. AICs were used to
provide a comparison between the OLS models and the GLMs.
For all 3 levels of SQLS-R4 explanatory variables the GLM
(gamma/log) was preferred over the OLS model for the EQ-5D
data, with the opposite being true for the SF-6D. CONCLU-
SIONS: There was little to choose between the 3 levels of models,
with the exception that much more variance was accounted for
by inclusion of all the items compared to the domain scores for
the EQ-5D OLS model. However, caution should be taken when
selecting which model to use, as the EQ-5D GLM model resulted
in higher utility scores than the SF-6D OLS model for patients
with good quality of life, whereas the opposite was true for
patients with poor quality of life.
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OBJECTIVES: Neurocognitive deﬁcits were shown to be associ-
ated with poorer functional outcomes. This study examines if
changes in cognitive deﬁcits are linked to changes in functional
outcomes in the long-term treatment of schizophrenia patients
in usual care, and whether this link is independent of changes in
EPS, Positive and Negative symptoms. METHOD: Participants
were 2144 patients who completed at least 1-year follow up in
the U.S. Schizophrenia Care and Assessment Program, a 3-year
observational study of patients with schizophrenia. Cognitive
impairment was assessed by the PANSS Cognitive Factor (PANSS
Cog). Functional outcomes were measured by the Quality of Life
Scale (QLS), the Global Assessment of Functioning Scale (GAF),
and the SCAP-Health Questionnaire (SCAP-HQ). Changes were
measured from baseline to the end of 1-year follow-up. Statisti-
cal analysis employed Pearson correlations, path analyses, 
and generalized linear models. RESULTS: Improvements in the
PANSS Cog were signiﬁcantly correlated with improvements in
occupational role functioning, social functioning, capacity to
engage in activities, participation in the community, GAF, daily
activities, employment status, and hourly wages. When adjust-
ing for EPS, Positive and Negative symptoms, cognitive improve-
ments were signiﬁcantly (p < 0.05) associated with improved
GAF, QLS total score, occupational role functioning, and hourly
wages. CONCLUSION: Improvements in cognitive deﬁcits
appear to be associated with improved functional outcomes.
Since the PANSS Cognitive Factor was used as a proxy measure
of cognition, current ﬁndings will require replications with neu-
ropsychological tests. Findings suggest that improving cognitive
